OFFER DEADLINE31/05/2019 12:00 - Europe/Brussels
EU RESEARCH FRAMEWORK PROGRAMMEH2020 / Marie Skłodowska-Curie Actions
ORGANISATION/COMPANYFundación para la Investigación Biomédica de Córdoba (FIBICO)
DEPARTMENTIMIBIC (Maimonides Biomedical Research Institute)
LABORATORYGC26 Clinical virology and zoonosis
Aim of the call
The Research group GC26 Clinical virology and zoonosis (https://www.imibic.org/grupo/45), led by Dr. Antonio Rivero Román is seeking to develop proposals with experienced researchers for submission under the Horizon 2020 Marie Skłodowska-Curie Individual Fellowships (https://tinyurl.com/y628flzb)
IMPORTANT: Applicants should check their CV against the eligibility and mobility conditions of Marie Skłodowska-Curie Actions.
Brief description of the Research Group
Our main research lines include the study of diagnostic and therapeutic tools and the design of prevention strategies for viral-zoonotic diseases prevalent in our environment that pose a health risk to the population. The objectives of our research are the acquisition and translation of knowledge into health problem solutions and promotion of the concept of One Health. These objectives are achieved by implementing collaborative, multidisciplinary research activities to solve health problems common to animals and humans.
The group successfully develops various lines of research in the field of HIV infection as well as co-infection with HIV and hepatotropic viruses co-infection. Our efforts in this area are demonstrated by more than 100 publications in international journals with a high impact factor that has generated an accumulated impact factor of over 420 points and three innovation patents registered in the last five years. In the context of zoonotic diseases, more than fifteen articles have been published, accumulating an impact factor of more than 100 points in only 5 years. Our group is also part of the AIDS Research Network (RIS, RD16/0025/0034) formed by numerous groups in Spain consolidated in HIV research.
Hepatitis E infection has been one of the main research lines of the project team in the latest years, having reached important aims in this field, notably:
The association of HEV persistent infection with idiopathic liver fibrosis in HIV positive patients [Rivero-Juarez et al PLoS One 2013], as well as the first report of chronic HEV hepatitis in immunocompromised patients in Spain [Neukam et al Clin Infect Dis 2013].
Reporting prevalence data of HEV in specific high-risk populations as HIV positive patients [Rivero-Juarez et al J Infection 2015], liver recipients [Rivero-Juarez et al Clin Microb Infect 2018], and blood donors [Rivero-Juarez et al J Viral Hep 2019].
The use of oral fluid for HEV diagnosis [Rivero-Juarez et al Zoon Publ Health 2018].
The prevalence of HEV infection in different animals as swine [Lopez-Lopez et al Vet Microb 2018], wild boar [Rivero-Juarez et al BMC Vet Res 2018], description of horses as new host of the HEV infection [Garcia-Bocanegra et al Transbound Emerg Dis 2019], and also the report of an outbreak linked to wild boar meat consumption [Rivero-Juarez et al Zoon Publ Health 2017].
Reported important clinical issues as isolation of HEV in breast milk [Rivero-Juarez et al Clin Infect Dis 2015], or reinfections in immunocompromised patients [Rivero-Juarez et al Clin Infect Dis 2017].
Finally, it should be highlighted that the one of the members of our research group has served as coordinator of the first guidelines for hepatitis E management in Spain hosted by SEIMC [Rivero-Juarez et al EIMC 2019]. All these milestones demonstrate our position as an international reference group in this field.
The HepE research program is a complex research study focus on epidemiology, diagnosis, treatment and prevention of Hepatitis E virus infection. This research program include studies with specifics objectives: evaluate the prevalence of infection in animal and different humans population, develop of new molecular procedures for the diagnosis of Hepatitis E virus including new emergent viral strains, evaluation of drugs with potential antiviral activity against hepatitis E virus, trace the origin of HEV using epidemiological and microbiological research, or to evaluate new potential source of transmission in animal models. The research team is composed by clinicians, vet, clinical pharmacologist, and epidemiologist from different Spanish region.
PhD in Veterinary medicine, Biology or similar
Specialized knowledge in one or more of the following domains: animal infectious diseases with zoonotic potential, design of interventional studies, experience with molecular biology processes and genomic data (phylogenetic analysis), cell cultures tuning and management, experience with animal models on infectious diseases, and expertise on next-generation sequencing procedures and analysis.
At least 3 papers as first of corresponding author in 1st decile journals
Both self-motivated and independent, and with ability to work in a team
Excellent level of spoken and written English and strong scientific communication skills
Spanish language skills will be helpful, though not required
The candidate must fulfil the eligibility and mobility conditions of Marie Skłodowska-Curie Actions.
The process consists of an analysis, evaluation and ranking of all CVs received. Following the evaluation, the highest ranked applicants may be called for a personal interview in order to evaluate more precisely the skills of the candidate.
How to Apply:
Applicants should send their CV to the following address: firstname.lastname@example.org stating clearly in the subject of the email the reference “PostdocMSCA2019GC26”.
Deadline for sending your CV: 31st May 2019.
Warning: Application emails that do not include reference will not be considered.
For more information about the Marie Skłodowska-Curie actions, see: http://ec.europa.eu/research/mariecurieactions/
The biomedical research institute, IMIBIC, located in Cordoba, southern Spain, is a partnership between the University of Cordoba and the Reina Sofia University Hospital. IMIBIC offers a multidisciplinary environment focused on results-oriented research and based on precision medicine and excellence in science. IMIBIC is accredited with the Excellence distinction from the Spanish National Institute of Health Carlos III, and has received the HR Excellence in Research award of the European Commission (HRS4R).
The Institute is structured in research groups that cooperate in the implementation of its various scientific programmes. Our major goal is to promote biomedical innovation as a powerful engine for economic and social development. IMIBIC offers an active environment in which to conduct high-level scientific research. Regular seminars and research events offer the opportunity to meet with national and international experts covering a diverse range of topics in biomedicine, providing ideal environment to strengthen the skills and knowledge of young scientists and fostering translational research by bringing together experimental basic and medical sciences.
IMIBIC is young and fast growing research center. It operates in a brand new IMIBIC building located within the UCO Health Sciences Campus and next to the University Hospital. It hosts a wide variety of core facilities for over 600 researchers, including the Biomedical Research Support Units with the latest technology equipment and laboratories to support the technical needs of the research community, as well as a Clinical Research Unit to support clinical trial research.
Cordoba is a medium sized city located in the hearth of Andalusia, with excellent transport connections to the main cities of Spain and both to the Mediterranean and Atlantic coasts. Rich in history and culture, Cordoba is a friendly and welcoming city with high standard of living, making it an ideal location for investigators wishing to carry out their research in Spain.